[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Military Institute od Medicine National Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":165},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,80,102,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644154","ocular-manifestations-of-granulomatosis-with-polyangiitis-100644154",false,"NCT07664709","Ocular Manifestations of Granulomatosis With Polyangiitis.","Inclusion Criteria:\n\nANCA positive vasculitis age 18- no limit patients with onset od the disease and patients already under treatment\n\n\\-\n\nExclusion Criteria:\n\n* no consent for ophthalmic examination\n* inability to udergo ophthalmic examination","ALL","18 Years",{"count":18,"type":19},70,"ESTIMATED","1 Day","OBSERVATIONAL","The current state of knowledge on ANCA-associated vasculitis (AAV) indicates that it is a group of autoimmune diseases in which small blood vessels in various organs are affected. Disease entities included in this group are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome).\n\nThese are rare diseases, with an incidence in Europe of approximately 20-25 cases per million people per year. There is a slight predominance among men, and the risk of developing the disease increases with age.\n\nANCA antibodies play a role in the pathogenesis of the disease, and inflammation within small vessels leads to damage of the vessel walls, resulting either in rupture or occlusion of the vessel lumen. Consequently, vital organs such as the kidneys, lungs, heart, nervous system, upper respiratory tract, gastrointestinal tract, and eyes may be affected.\n\nIf the disease is not diagnosed, untreated, or treated improperly, it can lead to irreversible failure of these organs and even death. Despite appropriate treatment, AAV diseases tend to relapse; therefore, therapy consists of two phases: induction therapy and maintenance therapy.\n\nCurrent EULAR\u002FEDTA guidelines for induction treatment of AAV recommend the use of cyclophosphamide (CYC) or rituximab (RTX) in combination with glucocorticosteroids in cases of severe disease. If remission is achieved after induction therapy, maintenance treatment should be initiated with drugs such as azathioprine, mycophenolate mofetil, methotrexate, or rituximab, combined with a low dose of glucocorticosteroids. Maintenance therapy should last no less than two years.\n\nThe study will focus on ophthalmological evaluation of patients diagnosed with ANCA-associated vasculitis. In this disease, all structures of the eye may be involved. The most common ocular manifestations include scleritis, keratitis, proptosis, inflammation of orbital tissues, nasolacrimal duct obstruction, and orbital involvement leading to proptosis, double vision, and restricted eye movement.\n\nUntil recently, the disease was often fatal. However, advances in diagnostics and current pharmacological treatment options, combined with appropriately aggressive immunosuppressive therapy, have significantly improved survival, enhanced patients' quality of life, and reduced mortality. Early diagnosis and prompt initiation of appropriate therapy are crucial.",[24,25,26,27],"GPA","Vasculitis","Microscopic Polyangiitis (MPA)","Churg-Strauss Syndrome (CSS)",[29,30,31,32,33],"ocular symptoms","octa","ocular manifestations","scleritis GPA","gpa ocular involvement","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2024-03-01",{"date":42,"type":19},"2026-12-31",{"name":44,"class":45},"Military Institute od Medicine National Research Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100628466","aqueous-humor-and-ocular-tissue-analysis-in-glaucoma-and-cataract-100628466","NCT07462000","Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract","Integrated Chemical and Proteomic Analysis of Aqueous Humor and Ocular Tissues in Glaucoma and Cataract Patients","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Scheduled for cataract surgery (phacoemulsification with intraocular lens implantation).\n* Ability to provide written informed consent.\n* For glaucoma arm: diagnosis of primary open-angle glaucoma (POAG) with coexisting cataract, and planned combined cataract surgery with glaucoma procedure.\n* For control arm: cataract without glaucoma and without other significant ocular pathology.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Pregnancy or breastfeeding.\n* Advanced visual impairment in the study eye (visual aquity worse than counting fingers).\n* Any glaucoma type other than primary open-angle glaucoma (e.g., angle-closure, secondary, neovascular glaucoma).\n* History of intraocular surgery in the study eye (including glaucoma surgery), vitreoretinal surgery, corneal transplantation, or refractive surgery.\n* Active or previous uveitis.\n* Other significant chronic ocular disease in the study eye (other than cataract and POAG in the glaucoma arm).\n* Inability to comply with study procedures or follow-up visits.",{"count":55,"type":19},40,"INTERVENTIONAL",[58],"NA","This observational study will compare proteomic and elemental profiles of aqueous humor and ocular tissues in patients with primary open-angle glaucoma (POAG) and cataract versus cataract controls without glaucoma. Samples collected during standard surgery will be analyzed using LC-MS\u002FMS and ICP-MS. The goal is to identify glaucoma-associated molecular patterns with potential diagnostic or prognostic relevance.",[61,62],"Primary Open-Angle Glaucoma (POAG)","Cataract",[64,65,62,66,67,68,69,70],"POAG","Glaucoma","Primary Open-Angle Glaucoma","Proteomics","Aqueous Humor","LC-MS\u002FMS","Deep Sclerectomy","2026-03-06",{"date":73,"type":38},"2026-03-10",{"date":75,"type":38},"2026-01-21",{"date":77,"type":19},"2027-11-30",{"name":44,"class":45},2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100612714","sutureless-technique-for-repositioning-and-scleral-fixation-of-the-capsular-bag---intraocular-lens-complex-with-permanent-use-of-iris-retractors-100612714","NCT07257172","Sutureless Technique for Repositioning and Scleral Fixation of the Capsular Bag - Intraocular Lens Complex With Permanent Use of Iris Retractors","Inclusion Criteria:\n\n* only adult men and women with subluxation lens\n\nExclusion Criteria:\n\n* previous ocular surgery\n* Fuchs' dystrophy\n* corneal haze or scarring\n* history of corneal transplantation\n* clinically active uveitis\n* advanced glaucoma\n* macular diseases that affect visual acuity (age-related macular degeneration, diabetic maculopathy)",{"count":55,"type":19},[58],"Sutureless technique for repositioning and scleral fixation of the capsular bag-intraocular lens complex with permanent use of iris retractors",[90],"Lens Subluxation",[90,92,93],"iris retractors","sutureless fixation","2025-11-20",{"date":96,"type":38},"2025-12-02",{"date":98,"type":38},"2021-05-28",{"date":100,"type":19},"2026-01",{"name":44,"class":45},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":56,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100517054","phase-2-randomized-double-blind-placebo-controlled-trial-of-the-efficacy-and-safety-of-tianeptine-in-the-treatment-of-covid-fog-symptoms-in-patients-after-covid-19-100517054","NCT06012552","Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.","Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19 With the Study of the Pathophysiology of the Phenomenon Using Positron Emission Tomography, Biochemical, Immunological and Electrophysiological Parameters.","COVMENT","Inclusion Criteria:\n\n* Written informed consent from the patient to participate in the clinical trial.\n* Age ≥ 18 years.\n* History of COVID-19 infection confirmed by a positive SARS-CoV-2 test result by RT- PCR or positive antigen test.\n* Subjective patient-reported cognitive decline after COVID-19 infection at Screening.\n* Cognitive dysfunction found at Screening, defined by the Montreal Scale for the Assessment of Cognitive Function (MoCA) as a score of less than 26.\n* Use of effective contraception by women of childbearing potential.\n\nExclusion Criteria:\n\n* Hypersensitivity to tianeptine.\n* Hypersensitivity to fluorodesoxyglucose (FDG).\n* History of allergy to drugs or other substances, which, in the Investigator's opinion, is a contraindication to participation in the study.\n* History of stroke.\n* Ever undergone and planned brain surgery at the time of the study.\n* Previously diagnosed organic damage to the central nervous system.\n* Diagnosed organic mental disorder.\n* Diagnosed bipolar affective disorder.\n* Diagnosed psychotic disorder.\n* History of active depressive episode, including those diagnosed at the time of study eligibility, requiring antidepressant treatment.\n* Diagnosed mental retardation.\n* Bipolar affective disorder in a first-degree relative.\n* Uncontrolled diabetes mellitus.\n* Severe renal failure with eGFR \\\u003C 30ml\u002Fmin\u002F1.73 m2.\n* cirrhosis of liver Severe liver cirrhosis (Child-Pugh class C ).\n* Claustrophobia.\n* Diagnosed chronic diseases that significantly worsen the patient's prognosis and quality of life, which, in the Investigator's opinion, may adversely affect the patient's participation in the study.\n* Active or past malignancy within the past 5 years, except for basal cell carcinoma of the skin and cervical cancer in situ in patients who have received radical treatment.\n* Active viral, bacterial, fungal, tuberculous, or parasitic infection.\n* History or presence of other relevant diseases which, in the Investigator's opinion, is a contraindication to participation in the study.\n* Positive pregnancy test performed on women of childbearing potential at screening or Visit 1.\n* Taking medications:\n\n  1. Non-selective MAO inhibitors within 14 days prior to screening,\n  2. Mianserin during screening.\n* Significant difficulty with peripheral venous cannulation.\n* Positive history of alcohol, drug, and psychoactive abuse\u002Fdependence.\n* Pregnancy or planning a pregnancy during the study period.\n* Breastfeeding or planning to breastfeed during the study period.\n* Current participation in another clinical trial.\n* Lack of patient compliance.",{"count":111,"type":19},140,[113],"PHASE2","COVID-19 is associated with a high risk of complications from the central nervous system. Syndrome of cognitive disorders- in terms of memory, attention or executive functions among COVID-19 convalescents is often called brain fog (covid fog - CF). CF leads to psychomotor retardation and chronic fatigue syndrome, resulting in poor functioning and low quality of life. CF may affect up to 81% of patients after COVID-19.\n\nPrevalence of CF may be even greater among patients with severe forms of COVID-19. In the preliminary assessment authors found that 83% of COVID-19 inpatients had at least mild cognitive impairment. Moreover, SARS-CoV-2 infection is associated with higher incidence of depression and anxiety disorders. CF pathogenesis is not fully understood. There exist no strict diagnostic criteria for it, as well as no therapeutic recommendations. Health care systems of many countries, including Poland, lack therapeutic programs addressed at patients with CF. Tianeptine may be a drug with potentially beneficial effects in CF. Neuroprotective, antidepressive, sleep-improving and anxiolytic properties of tianeptine allow it to choose as a candidate for CF amelioration. There is also data supporting the thesis that patients with CF may benefit from short-term group therapy. It has been proven to improve quality of life, reduce stress, and improve cognitive function in non-MC cognitive disorders.\n\nExpected research results: A database will be created from the collected clinical, laboratory and additional data. Statistical models will be created to predict: the duration of disorders, response to therapy, the final result of treatment. Among the markers of CNS damage, those which correlates with the patient's condition will be selected.\n\nThe study will allow to estimate the prevalence of CF in the population. PET-CT and auditory evoked potentials also will be used to expand knowledge in the field of CF.\n\nBased on the existing data, an improvement is expected in all investigated participants as a result of rehabilitation and psychotherapy.\n\nAdditional improvement is expected in the tianeptine group. Improvement will be defined as: reduction in the severity of anxiety and depression disorders, reduction in the severity of cognitive disorders, improvement in the quality of life. The results will be used to develop a new diagnostic and therapeutic pathway and a comprehensive intervention program in CF.",[116],"Nervous System Diseases",[118,119,120,121,122,123,124,125,126],"COVID-19","memory problems","Covid Fog","brain fog","COVID-19 brain fog","lack of mental clarity","poor concentration","headaches","confusion","2023-08-24",{"date":129,"type":38},"2023-08-25",{"date":131,"type":38},"2023-02-17",{"date":133,"type":19},"2027-10-31",{"name":44,"class":45},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":56,"phases":145,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":46},"100494338","phase-3-ketoanalogues-for-muscle-mass-loss-in-nephrotic-syndrome-100494338","NCT05716880","Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome","FORMA - a Multicenter Randomized-controlled Trial to Evaluate the Efficacy and Safety of Ketoanalogues of Essential Amino Acids in Prophylaxis of Protein-energy Wasting in Nephrotic Syndrome","FORMA","Inclusion Criteria:\n\n* Nephrotic syndrome with serum albumin \\\u003C 3.0 g\u002FdL and daily proteinuria of \\> 3.5 g\u002Fday or \\> 50 mg\u002Fkg;\n* New diagnosis or relapse of nephrotic syndrome (defined as: proteinuria of \\\u003C 2.0 g\u002Fday or uPCR \\\u003C 2000 mg\u002Fg in the last 6 months prior to relapse and prednison dose equal to or less than 10 mg\u002Fday in the last 3 months prior relapse);\n* Glomerular filtration rate qual to or higher than 30 mL\u002Fmin\u002F1.73m2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n\nExclusion Criteria:\n\n* Diabetic kidney disease;\n* Small vessels vasculitis;\n* Systemic lupus erythematosus;\n* Positive antinuclear antibodies, anti-dsDNA or antineutrophil cytoplasmic antibodies (ANCA);\n* Positive anti-HIV or anti-hepatitis C antibodies, HBsAg;\n* HbA1c \\>7%;\n* Monoclonal gammopathy;\n* Pregnancy;\n* Body mass index \\>= 40 kg\u002Fm2;\n* Severe acute or chronic disease affecting nutritional status;\n* Neoplasm;\n* Contraindication to Ketosteril;\n* Alcohol or drug abuse;\n* Mental disorders;\n* Failure to comply with medical recommendations, lack of cooperation;\n* Participation in other clinical trial or the use of Ketosteril in the last 1 year prior to screening.",{"count":144,"type":19},150,[146],"PHASE3","The goal of this non-commercial clinical trial is to assess efficacy and safety of ketoanalogues of essential amino acids in the prevention of protein-energy wasting in nephrotic syndrome.",[149],"Nephrotic Syndrome",[151,152,153,154,155,156],"nephrotic syndrome","protein-energy wasting","neph-PEW","lean tissue mass","Ketosteril","ketoanalogues","2023-01-30",{"date":159,"type":38},"2023-02-08",{"date":161,"type":38},"2023-01-03",{"date":163,"type":19},"2027-08-31",{"name":44,"class":45},""]